PT  - JOURNAL ARTICLE
AU  - Galkina, Ksenia
AU  - Nosova, Elena
AU  - Krasnova, Maria
AU  - Khakhalina, Anastasia
AU  - Isakova, Alexandra
AU  - Safonova, Svetlana
TI  - Determination of the type of acetylation in adult patients with lung tuberculosis
AID  - 10.1183/13993003.congress-2020.1449
DP  - 2020 Sep 07
TA  - European Respiratory Journal
PG  - 1449
VI  - 56
IP  - suppl 64
4099  - http://erj.ersjournals.com/content/56/suppl_64/1449.short
4100  - http://erj.ersjournals.com/content/56/suppl_64/1449.full
SO  - Eur Respir J2020 Sep 07; 56
AB  - Introduction: Isoniazid is the main antitubercular drug. Its toxicity is closely connected with mutations in such human genes as NAT2 (С481Т, G590A, G857A, C341T)The Aim: of our investigation was a determination of the type of acetylation in TB in adult patients using molecular-genetic tests.Materials and Methods: We studied 150 samples of human DNA extracted from the blood of 150 adult patients with lung TB from the hospitals of MRCCTC. Detection of mutations in NAT2 genes performed by allele-specific real-time PCR test (LTD Sintol, Russia). We compared the PCR-results with the biochemical parameters of blood (the level of alanine- and aspartate aminotransferase before and 2 months after of isoniazid administration). Also, we paid our attention to the presence of concomitant diseases, such as HIV infection, hepatitis B and C, diabetes mellitus and bad habits (alcohol and smoking).Results: Out of the 150 adult TB patients, 66 (44%) had slow, and 84 (56%) had a fast acetylation type. Toxic hepatitis developed in 58% of slow and 21% with a fast acetylation type. Thus, the risk of isoniazid toxicity in adults with a slow acetylation type increased by 4,98 times, the sensitivity of the method was 57.8%, specificity 78.6%. PPR 68%, POR 70%.Conclusion: Genetic tests application helps to tailor a chemotherapy regimen to the patient, according to his metabolic pattern in a short time.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 1449.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).